Eli Lilly and Company
LLY · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $695,267,060 | $524,266,007 | $347,614,583 | $263,418,032 |
| - Cash | $3,268,400 | $2,818,600 | $2,067,000 | $3,818,500 |
| + Debt | $33,644,200 | $25,225,300 | $16,238,600 | $16,884,700 |
| Enterprise Value | $725,642,860 | $546,672,707 | $361,786,183 | $276,484,232 |
| Revenue | $45,042,700 | $34,124,100 | $28,541,400 | $28,318,400 |
| % Growth | 32% | 19.6% | 0.8% | – |
| Gross Profit | $36,624,400 | $27,041,900 | $21,911,600 | $21,005,600 |
| % Margin | 81.3% | 79.2% | 76.8% | 74.2% |
| EBITDA | $15,227,600 | $8,567,800 | $8,660,500 | $8,042,900 |
| % Margin | 33.8% | 25.1% | 30.3% | 28.4% |
| Net Income | $10,590,000 | $5,240,400 | $6,244,800 | $5,581,700 |
| % Margin | 23.5% | 15.4% | 21.9% | 19.7% |
| EPS Diluted | 11.71 | 5.8 | 6.57 | 5.85 |
| % Growth | 101.9% | -11.7% | 12.3% | – |
| Operating Cash Flow | $8,817,900 | $4,240,100 | $7,585,700 | $7,365,900 |
| Capital Expenditures | -$8,403,600 | -$7,392,100 | -$2,985,300 | -$1,978,400 |
| Free Cash Flow | $414,300 | -$3,152,000 | $4,600,400 | $5,387,500 |